Upon joining the study, you will be required to sign an informed consent form. This form confirms that you understand the purpose and procedures of the study and agree to participate.

You must meet specific criteria, such as actively receiving daratumumab or other study treatments for multiple myeloma, and continue to benefit from the treatment without experiencing disease progression or unmanageable side effects.

An initial assessment will be conducted to ensure you meet all the necessary criteria. This includes a negative pregnancy test for female participants of childbearing potential and agreement to use effective contraception methods during the study.

Male participants must agree to use condoms during activities that allow for the passage of ejaculate and not to donate sperm during the study and for a specified period after the last dose.

You will receive daratumumab as part of your treatment regimen. This medication is administered through intravenous use or infusion.

Other medications may include dexamethasone, pomalidomide, lenalidomide, and carfilzomib, which are taken orally or through infusion, depending on the specific treatment plan.

Throughout the study, your health and response to the treatment will be closely monitored. This includes regular check-ups and assessments to ensure the treatment’s effectiveness and manage any side effects.

You will continue to receive the study treatment as long as you benefit from it and do not experience any significant adverse effects.

The study will continue until no more patients require access to daratumumab through this study, or until alternative access to the medication is available.

The estimated end date for the study is March 31, 2026, but your participation may end earlier if you no longer benefit from the treatment or if you choose to withdraw.